Search Results

There are 8167 results for: content related to: A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

  1. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  2. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  3. You have free access to this content
    Interleukin-1 inhibitors for acute gout

    Intervention Review

    The Cochrane Library

    Francisca Sivera, Mihir D Wechalekar, Mariano Andrés, Rachelle Buchbinder and Loreto Carmona

    Published Online : 1 SEP 2014, DOI: 10.1002/14651858.CD009993.pub2

  4. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

    The Journal of Clinical Pharmacology

    Volume 53, Issue 12, December 2013, Pages: 1240–1251, Abhijit Chakraborty, Linh M. Van, Andrej Skerjanec, David Floch, Ulf R. Klein, Gerhard Krammer, Gangadhar Sunkara and Dan Howard

    Version of Record online : 30 SEP 2013, DOI: 10.1002/jcph.162

  5. You have full text access to this OnlineOpen article
    Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics

    CPT: Pharmacometrics & Systems Pharmacology

    Volume 1, Issue 9, September 2012, Pages: 1–10, S Ait-Oudhia, PJ Lowe and DE Mager

    Version of Record online : 26 SEP 2012, DOI: 10.1038/psp.2012.6

  6. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

    The Journal of Clinical Pharmacology

    Volume 56, Issue 12, December 2016, Pages: 1516–1527, Haiying Sun, Linh M. Van, David Floch, Xuemin Jiang, Ulf R. Klein, Ken Abrams and Gangadhar Sunkara

    Version of Record online : 8 JUN 2016, DOI: 10.1002/jcph.754

  7. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  8. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1088–1096, A. Rissanen, C. P. Howard, J. Botha, T. Thuren and for the Global Investigators

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01637.x

  9. Real-world experience and impact of canakinumab in cryopyrin-associated periodic syndrome: Results from the French observational study ENVOL

    Arthritis Care & Research

    Accepted manuscript online: 16 SEP 2016, I. Kone-Paut, P. Quartier, O. Fain, G. Grateau, P. Pillet, P. Le Blay, F. Bonnet, V. Despert, K. Stankovic Stojanovic, L. Willemin, S. Quéré, O. Reigneau and E. Hachulla

    DOI: 10.1002/acr.23083

  10. Canakinumab for the treatment of adult and pediatric cryopyrin-associated periodic syndromes (CAPS)

    Drug Development Research

    Volume 72, Issue 7, November 2011, Pages: 553–560, Aarat M. Patel and Kathryn S. Torok

    Version of Record online : 23 NOV 2011, DOI: 10.1002/ddr.20465

  11. You have free access to this content
    Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

    Arthritis & Rheumatism

    Volume 62, Issue 10, October 2010, Pages: 3064–3076, Alexander So, Marc De Meulemeester, Andrey Pikhlak, A. Eftal Yücel, Dominik Richard, Valda Murphy, Udayasankar Arulmani, Peter Sallstig and Naomi Schlesinger

    Version of Record online : 8 JUN 2010, DOI: 10.1002/art.27600

  12. You have free access to this content
    Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

    Arthritis & Rheumatology

    Volume 68, Issue 1, January 2016, Pages: 218–228, Alexei A. Grom, Norman T. Ilowite, Virginia Pascual, Hermine I. Brunner, Alberto Martini, Daniel Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Karolynn Leon, Karine Lheritier and Ken Abrams

    Version of Record online : 23 DEC 2015, DOI: 10.1002/art.39407

  13. Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 3, September 2012, Pages: 352–359, I Demin, B Hamrén, O Luttringer, G Pillai and T Jung

    Version of Record online : 4 JUL 2012, DOI: 10.1038/clpt.2012.69

  14. CSF cytokines correlate with aseptic meningitis and blood brain barrier function in Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

    Arthritis & Rheumatology

    Accepted manuscript online: 24 JAN 2017, Jackeline Rodriguez-Smith, Yen-Chih Lin, Wanxia Li Tsai, Hanna Kim, Gina Montealegre-Sanchez, Dawn Chapelle, Yan Huang, Cailin H. Sibley, Massimo Gadina, Robert Wesley, Bibiana Bielekova and Raphaela Goldbach-Mansky

    DOI: 10.1002/art.40055

  15. You have free access to this content
    Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome–related uveitis

    Arthritis & Rheumatism

    Volume 65, Issue 2, February 2013, Pages: 513–518, Gabriele Simonini, Zhaohui Xu, Roberto Caputo, Cinzia De Libero, Ilaria Pagnini, Virginia Pascual and Rolando Cimaz

    Version of Record online : 28 JAN 2013, DOI: 10.1002/art.37776

  16. You have free access to this content
    Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

    European Journal of Immunology

    Volume 46, Issue 4, April 2016, Pages: 1030–1046, Susanne M. Cabrera, Xujing Wang, Yi-Guang Chen, Shuang Jia, Mary L. Kaldunski, Carla J. Greenbaum, the Type 1 Diabetes TrialNet Canakinumab Study Group, Thomas Mandrup-Poulsen, the AIDA Study Group and Martin J. Hessner

    Version of Record online : 21 JAN 2016, DOI: 10.1002/eji.201546005

  17. You have free access to this content
    2017 ACR/ARHP Pediatric Rheumatology Symposium

    Arthritis & Rheumatology

    Volume 69, Issue S4, April 2017, Pages: 1–230,

    Version of Record online : 22 APR 2017, DOI: 10.1002/art.40135

  18. Role of Interleukin-1 Inhibitors in the Management of Gout

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 7, July 2013, Pages: 744–753, Tran H. Tran, Jacqueline T. Pham, Hira Shafeeq, Kendra R. Manigault and Vibhuti Arya

    Version of Record online : 3 APR 2013, DOI: 10.1002/phar.1265

  19. Challenges and considerations for development of therapeutic proteins in pediatric patients

    The Journal of Clinical Pharmacology

    Volume 55, Issue S3, March 2015, Pages: S103–S115, Yi Zhang, Xiaohui Wei, Gaurav Bajaj, Jeffrey S. Barrett, Bernd Meibohm, Amita Joshi and Manish Gupta

    Version of Record online : 23 FEB 2015, DOI: 10.1002/jcph.382

  20. You have free access to this content
    Canakinumab for the Treatment of Children With Colchicine-Resistant Familial Mediterranean Fever: A 6-Month Open-Label, Single-Arm Pilot Study

    Arthritis & Rheumatology

    Volume 66, Issue 11, November 2014, Pages: 3241–3243, Riva Brik, Yonatan Butbul-Aviel, Sari Lubin, Eliad Ben Dayan, Tamar Rachmilewitz-Minei, Lillian Tseng and Philip J. Hashkes

    Version of Record online : 26 OCT 2014, DOI: 10.1002/art.38777